Track record · closed signal

Novavax Inc (NVAX) — closed signal from April 28, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 27, 2026 — -6.8% at the close.

Predicted vs. what happened

NVAX price · publication thesis → realized outcomesplit-adjusted
$8.04 Published $9.48 Target $7.49 Window close $11.61 Peak
$7.40 – $8.20Entry zone — fair-value band
$8.04Published — price the day we called it
$9.48Target — the price the thesis aimed for
$11.61Peak — highest point inside the window, not a realized return
$7.49Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 8 days.

At window close
-6.8%
realized, from the publication price to the last close inside the window
Peak gain
+44.4%
peak, from the publication price — not a realized return
S&P 500, same window
+4.1%
SPY over the identical days, dividend-adjusted
Window close
$7.49
last close inside the window, ended July 27, 2026
Peak price
$11.61
peak on May 27, 2026 — not a realized return
Days to target
8

The thesis — published April 28, 2026

Predicted growth
+18%
over the measurement window
Target price
$9.48
the price the thesis aimed for
Entry zone
$7.40 – $8.20
the fair-value band we waited for
Price at publication
$8.04
published April 28, 2026
Confidence
64%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Novavax is a high-risk biotech pick. A recent analyst note pushing the stock higher on governance news gave it a short-term lift, and the company has enough cash to withstand pressure. Vaccine work is promising, but earnings can swing widely and heavy short positions can make the share price jumpier, so confidence is intentionally modest.

Primary drivers

  • Analyst target lift highlights possible governance improvements
  • Cash on hand helps the company ride out biotech ups and downs
  • Vaccine technology keeps future opportunities open
  • High short interest and uneven results can make the stock volatile

How it played out

NVAX: target reached in 8 days

Lyra published NVAX at $8.04 with an expected gain of 18% and a $9.48 target. The thesis described it as a high-risk biotech pick with modest confidence. It pointed to an analyst target lift, cash on hand, vaccine technology, high short interest, and uneven results.

The shares reached the target in 8 days. They later peaked at $11.61 on May 27, a gain of 44.4%. By the end of the window, they had fallen to $7.49. The thesis played out within the measured period because the target was reached, though the gain did not hold through the close.

What happened during the window

On May 6, 2026, Novavax reported first-quarter revenue of $140 million and reiterated its 2026 revenue framework of $230 million to $270 million.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVAX signals